Regarding ACSL4, its knockdown has been associated with cisplatin, paclitaxel, and doxorubicin sensitivity in TNBC, and docetaxel sensitivity in prostate cancer [65–67]. This evidence concerns the gene ACSL4 and prostate cancer.